NewTimeSpace News: On 27 August 2026, TYK MEDICINES-B (02410.HK) announced that its self-developed next-generation EGFR-TKI dovatinib mesylate tablets (TY-9591) have been granted conditional NMPA approval for the first-line treatment of adult patients with locally advanced or metastatic NSCLC harboring EGFR 19del or L858R mutations with CNS metastases; the drug is a differentiated deuterated innovation derived from osimertinib, and the Company has initiated multiple monotherapy and combination studies around the product.
NewTimeSpace News: On 27 August 2026, ZHENRO SERVICES (06958.HK) announced the appointment of Mr. Wang Yi, aged 44 and currently the Company Secretary and CFO, as an executive director with effect from the same day, with the appointment lasting until the conclusion of the next annual general meeting and a basic salary of RMB 680,000 per annum.
NewTimeSpace News: On 27 August 2026, IMMUNEONCO-B (01541.HK) announced that the first patient has been dosed in the Phase II trial (IMM2510-HCC-201) of IMM2510 plus IMM27M as first-line treatment for advanced HCC; the Phase Ib trial has determined the RP2D with expansion studies in esophageal squamous cell carcinoma and other solid tumors, and 6 evaluable patients in dose escalation achieved an ORR of 50%; the combination achieves synergistic coverage of PD-L1, VEGF and CTLA-4, with a Rule 18A.05 warning statement included.
NewTimeSpace News: On 27 August 2026, COOLPAD GROUP (02369.HK) announced that its wholly-owned subsidiary Digital Tech sold 248 call options covering 24,800 MSTR shares for a total premium of USD 71,442 (approximately HKD 557,962), with a strike price of USD 140.00 per share and expiry on 11 September 2026; if all options are exercised, the Group expects to recognize a gain of approximately USD 1.16 million, and the sale constitutes a discloseable transaction exempt from shareholders' approval.
NewTimeSpace News: On 27 August 2026, SHIMAO GROUP (00813.HK) announced that Guotong Trust had filed a winding-up petition against the Company with the High Court, relating to judgment debts of RMB 2,497,885,817 arising from four judgments by Mainland courts, with the first hearing fixed for 11 November 2026; no winding-up order has been issued, the Company will resolutely oppose the petition, and the announcement cautioned on the effects of Section 182 of the Companies Ordinance and potential HKSCC service suspensions.
NewTimeSpace News: On 27 August 2026, SHIMAO SERVICES (00873.HK) announced that its holding company Shimao Group had received a winding-up petition filed by Guotong Trust relating to judgment debts of RMB 2,497,885,817 arising from four judgments by Mainland courts; no winding-up order has been issued by the High Court, and the Board believes the petition will have no material impact on the Group's financial performance and operations.
NewTimeSpace News: On 27 August 2026, FOSUN PHARMA (02196.HK) announced that GR1803 injection (weliteitumab injection; trade name Weikenuo), licensed by its controlling subsidiary Yaoyou Pharmaceutical, has been granted conditional NMPA approval for adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy; the drug is a BCMA×CD3 bispecific antibody in a 20mg (2ml) per vial specification classified as Class 1 therapeutic biologics, with global sales of same-target drugs reaching approximately USD 1.139 billion in 2025, and an MAH transfer will subsequently be advanced.
NewTimeSpace News: On 27 August 2026, CHENGDU EXPWAY (01785.HK) announced that non-executive director Ms. Wu Haiyan resigned with immediate effect due to retirement, also ceasing her roles on three board committees; the Board proposed appointing Ms. Jiang Na as a non-executive director, subject to shareholders' approval; following Ms. Wu's departure, the audit committee fell below three members and the board's gender diversity no longer complies with the Listing Rules, with the Company aiming to fill vacancies within three months.
NewTimeSpace News: On 27 August 2026, HK ROBOTICS (00370.HK) announced the latest progress of its cooperation with Danta Robotics: three core objectives including the establishment of the joint venture, IP licensing and operation team formation have been basically achieved, with the exclusive license for the Danta Cloud Brain expiring in September 2028; robotics and computing power revenue for the year ended 31 March 2026 was approximately HKD 169.6 million, of which about 83% related to products using Danta's licensed IP; the 2025 revenue target was not fully achieved due to delays, with the parties negotiating adjustments and the Group seeking to reduce its 49% stake in the joint venture; the Group is independently developing the "Hong Kong Robotics Cloud Brain" expected to be completed before September 2028, after which license fees will no longer be payable.
NewTimeSpace News: August 27, 2026, ZOOMLION(01157.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 27.14 billion, increased by 9.17% YoY
NewTimeSpace News: August 27, 2026, JW THERAP-B(02126.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 111.35 million, increased by 4.71% YoY.
NewTimeSpace News: On 27 August 2026, SSY GROUP (02005.HK) announced that it has obtained NMPA production registration approvals for gadobutrol injection (7.5ml: 4.5354g, Category 4 chemical drug) and indocyanine green for injection (25mg, Category 3 chemical drug), both deemed to have passed consistency evaluation; the products are used for contrast-enhanced MRI examinations and the diagnosis of liver diseases respectively, and together with the Group's already-registered APIs complete its integrated layout, supporting expansion into the medical imaging and critical care markets.
NewTimeSpace News: On 27 August 2026, IB SETTLEMENT (00147.HK) announced at the request of the Exchange that, in response to an increase in the share price and trading volume, the Board is not aware of any reasons for the fluctuation; the Company is in preliminary discussions with an independent third party over a potential investment opportunity in the technology sector, with terms not yet finalized and no formal agreement signed, and the potential investment, if materialized, may constitute a discloseable transaction.
NewTimeSpace News: On 27 August 2026, LIVZON PHARMA (01513.HK) announced that its controlling subsidiary has received the NMPA Drug Registration Certificate for lecankitug injection (subcutaneous injection), with approval number Guoyao Zhunzi S20260065 valid until 24 August 2031; the drug is China's first independently developed IL-17A/F dual-target biologic for adult patients with moderate-to-severe plaque psoriasis, with Phase III data showing superiority over secukinumab control in onset of action, lesion clearance and long-term efficacy, and cumulative R&D investment of approximately RMB 223.31 million.
NewTimeSpace News: On 27 August 2026, SUN KONG HLDGS (08631.HK) announced that it received resumption guidance from HKEX on 24 August 2026, covering six conditions including publication of outstanding financial results, independent forensic investigation and internal control review; trading has been suspended since 2 July 2026, and if trading is not resumed by 1 July 2027, HKEX may proceed with the cancellation of the Company's listing.
NewTimeSpace News: On 27 August 2026, CSPC PHARMA (01093.HK) announced that its SYH2092 injection, an amylin receptor agonist, has been approved by the NMPA to conduct clinical trials in China; preclinical studies showed higher target agonistic activity, significant weight loss effects and durable maintenance versus multiple amylin analogues in development, with synergistic weight loss when combined with the Group's GLP-1/GIP receptor dual biased agonist, potentially benefiting weight management in obesity and glycemic control in adult T2DM patients.
